Cargando…
Prevalence of Prohibited Substance Use and Methods by Female Athletes: Evidence of Gender-Related Differences
To achieve optimal sports performances, women and men may show specific doping practices because of the physiological and psychological gender differences, but there are few data on this topic. Here, we report the apparent use of prohibited substances and methods by female athletes based on analyses...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172204/ https://www.ncbi.nlm.nih.gov/pubmed/35685685 http://dx.doi.org/10.3389/fspor.2022.839976 |
_version_ | 1784721837354123264 |
---|---|
author | Collomp, Katia Ericsson, Magnus Bernier, Nathan Buisson, Corinne |
author_facet | Collomp, Katia Ericsson, Magnus Bernier, Nathan Buisson, Corinne |
author_sort | Collomp, Katia |
collection | PubMed |
description | To achieve optimal sports performances, women and men may show specific doping practices because of the physiological and psychological gender differences, but there are few data on this topic. Here, we report the apparent use of prohibited substances and methods by female athletes based on analyses of the doping tests collected by the French Anti-Doping Agency from 2013 to 2019. We compared the frequency of use and the ergogenic and side effects to those of their male counterparts. The results revealed lower use of prohibited substances in female vs. male athletes, with significantly fewer anabolic agents, hormone and metabolic modulators, and cannabinoids. Gender specificity in utilization of substance classes was also shown. Relatively lower use of hormone modulators and cannabinoids and higher use of beta-2 agonists, diuretics and glucocorticoids were found in the woman cohort compared with men cohort, combined with the different choice of substances, possibly because of the altered ergogenic and/or side effects. However, no impact due to gender regarding the sports disciplines was observed, with both women and men showing similar use of anabolic agents, mainly in the anaerobic sports, and EPO and corticoids, mainly in endurance or mixed sports. Further studies are needed to put these French data into a global perspective, comparing uses across countries and exploring possible new developments in the fight against doping in women. |
format | Online Article Text |
id | pubmed-9172204 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91722042022-06-08 Prevalence of Prohibited Substance Use and Methods by Female Athletes: Evidence of Gender-Related Differences Collomp, Katia Ericsson, Magnus Bernier, Nathan Buisson, Corinne Front Sports Act Living Sports and Active Living To achieve optimal sports performances, women and men may show specific doping practices because of the physiological and psychological gender differences, but there are few data on this topic. Here, we report the apparent use of prohibited substances and methods by female athletes based on analyses of the doping tests collected by the French Anti-Doping Agency from 2013 to 2019. We compared the frequency of use and the ergogenic and side effects to those of their male counterparts. The results revealed lower use of prohibited substances in female vs. male athletes, with significantly fewer anabolic agents, hormone and metabolic modulators, and cannabinoids. Gender specificity in utilization of substance classes was also shown. Relatively lower use of hormone modulators and cannabinoids and higher use of beta-2 agonists, diuretics and glucocorticoids were found in the woman cohort compared with men cohort, combined with the different choice of substances, possibly because of the altered ergogenic and/or side effects. However, no impact due to gender regarding the sports disciplines was observed, with both women and men showing similar use of anabolic agents, mainly in the anaerobic sports, and EPO and corticoids, mainly in endurance or mixed sports. Further studies are needed to put these French data into a global perspective, comparing uses across countries and exploring possible new developments in the fight against doping in women. Frontiers Media S.A. 2022-05-24 /pmc/articles/PMC9172204/ /pubmed/35685685 http://dx.doi.org/10.3389/fspor.2022.839976 Text en Copyright © 2022 Collomp, Ericsson, Bernier and Buisson. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Sports and Active Living Collomp, Katia Ericsson, Magnus Bernier, Nathan Buisson, Corinne Prevalence of Prohibited Substance Use and Methods by Female Athletes: Evidence of Gender-Related Differences |
title | Prevalence of Prohibited Substance Use and Methods by Female Athletes: Evidence of Gender-Related Differences |
title_full | Prevalence of Prohibited Substance Use and Methods by Female Athletes: Evidence of Gender-Related Differences |
title_fullStr | Prevalence of Prohibited Substance Use and Methods by Female Athletes: Evidence of Gender-Related Differences |
title_full_unstemmed | Prevalence of Prohibited Substance Use and Methods by Female Athletes: Evidence of Gender-Related Differences |
title_short | Prevalence of Prohibited Substance Use and Methods by Female Athletes: Evidence of Gender-Related Differences |
title_sort | prevalence of prohibited substance use and methods by female athletes: evidence of gender-related differences |
topic | Sports and Active Living |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172204/ https://www.ncbi.nlm.nih.gov/pubmed/35685685 http://dx.doi.org/10.3389/fspor.2022.839976 |
work_keys_str_mv | AT collompkatia prevalenceofprohibitedsubstanceuseandmethodsbyfemaleathletesevidenceofgenderrelateddifferences AT ericssonmagnus prevalenceofprohibitedsubstanceuseandmethodsbyfemaleathletesevidenceofgenderrelateddifferences AT berniernathan prevalenceofprohibitedsubstanceuseandmethodsbyfemaleathletesevidenceofgenderrelateddifferences AT buissoncorinne prevalenceofprohibitedsubstanceuseandmethodsbyfemaleathletesevidenceofgenderrelateddifferences |